Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.49 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.48 |
| ▸ | TUBB | P07437 | 2/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.48 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.48 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.48 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.48 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.48 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.48 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.48 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.48 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.48 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.48 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.48 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.48 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7146375 | 0.99 | CYP1A2 (0.51) | CYP1A2CYP2C19CYP1A1CYP1B1TUBB4A | |
| Bromide SCHEMBL6507643 | 0.88 | ALDH1A1 (0.55) | CYP1A2CYP1A1CYP1B1ABCB1LMNA | |
| SCHEMBL7143763 | 0.86 | ALDH1A1 (0.56) | CYP1A2CYP1A1CYP1B1ABCB1LMNA | |
| Bromide SCHEMBL6282381 | 0.81 | KMT2A (0.53) | CYP1A2CYP1A1CYP1B1LMNA | |
| Bromide SCHEMBL6279797 | 0.80 | TDP1 (0.46) | LMNA | |
| Bromide SCHEMBL6285575 | 0.80 | ALDH1A1 (0.54) | CYP1A2CYP1A1CYP1B1LMNA | |
| SCHEMBL6498922 | 0.79 | KMT2A (0.55) | CYP1A2CYP1A1CYP1B1LMNA | |
| SCHEMBL7142887 | 0.79 | TDP1 (0.47) | — | |
| SCHEMBL7144956 | 0.79 | ALDH1A1 (0.55) | CYP1A2CYP1A1CYP1B1LMNA | |
| Bromide SCHEMBL6282444 | 0.77 | SMN1; SMN2 (0.50) | CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962933-B1 | Method for inhibiting p38 MAP kinase or TNF-α production using a 1,3-thiazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-08 | — | — | US | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1027050-B1 | 1,3-THIAZOLES AS ADENOSINE A3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ALLERGY, ASTHMA AND DIABETES | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-01-14 | — | — | EP | disclosed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-1205478-A1 | p38MAP KINASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2002-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | CYP1A2 3863/4885CYP2C19 4693/4885CYP1A1 4026/4885 |
| US-20040097555-A1 | Concomitant drugs | TNF, CHUK, CNKSR1 | CYP1A2 1072/4885CYP2C19 1906/4885CYP1A1 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.